テキサスにおける悪性黒色腫の臨床試験
テキサス内の拠点で、悪性黒色腫に関する77件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Study of BI 3810944 in Patients With Advanced Cancer
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07224425A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Texas Oncology - Austin Midtown, Midtown Medical Center I, Austin
- Texas Oncology - Austin Central, Central Austin Cancer Center, Austin
- Texas Oncology - South Austin, South Austin Cancer Center, Austin
- 他13件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06246916Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06548789A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- Dell Children's Medical Center of Central Texas, Austin
- UT MD Anderson Cancer Center, Houston
被験者募集中第2相
25歳以下 · 全性別 · 2026/09/24更新 · NCT07621614Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379Pan-tumor MRD Study
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
- Community Clinical Trials, Kingwood
- Christus St. Michael's, Texarkana
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404Intratumoral N17350 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07339176Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Texas Oncology (Balcones) - SCRI, Austin
- MD Anderson Cancer Center, Houston
- START South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- M D Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/18更新 · NCT04038619A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0085, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07492680ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UT Southwestern Medical Center, Dallas
- DHR Health Advance Care Center, Edinburg
- The Center for Cancer and Blood Disorders, Forth Worth
- 他1件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- UT Southwestern, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07288112Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Texas Oncology, Austin
- Texas Oncology - Dallas SCRI, Dallas
- University of Texas-MD Anderson, Houston
- 他2件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07287917A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- MD Anderson, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT04913285A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07070232Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT06683755Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06545682Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他12件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/21更新 · NCT01772771A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Houston
- Research Site, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Houston Methodist Hospital, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT04895709A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- START San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06880549Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/10更新 · NCT04594187A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06910657A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT04198766Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/16更新 · NCT06060613Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/16更新 · NCT05704647Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
12歳〜50歳 · 全性別 · 2026/07/15更新 · NCT03093909A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0054), Dallas
被験者募集中第1/2相
6 Months – 17 Years · 全性別 · 2026/07/06更新 · NCT02332668Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- JPS Health Network, Forth Worth
- Baylor Scott and White Biorepository, Temple
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/11更新 · NCT04771520ClinicalTrials.govより、2026/10/04時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。